MX2018001318A - Sistema de administracion transdermica. - Google Patents
Sistema de administracion transdermica.Info
- Publication number
- MX2018001318A MX2018001318A MX2018001318A MX2018001318A MX2018001318A MX 2018001318 A MX2018001318 A MX 2018001318A MX 2018001318 A MX2018001318 A MX 2018001318A MX 2018001318 A MX2018001318 A MX 2018001318A MX 2018001318 A MX2018001318 A MX 2018001318A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydroetorphine
- hours
- less
- transdermal delivery
- plasma concentration
- Prior art date
Links
- 230000037317 transdermal delivery Effects 0.000 title abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 3
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513441.4A GB201513441D0 (en) | 2015-07-30 | 2015-07-30 | Transdermal delivery system |
| PCT/GB2016/052307 WO2017017452A1 (en) | 2015-07-30 | 2016-07-28 | Transdermal delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001318A true MX2018001318A (es) | 2018-08-15 |
Family
ID=54062902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001318A MX2018001318A (es) | 2015-07-30 | 2016-07-28 | Sistema de administracion transdermica. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180221299A1 (enExample) |
| EP (1) | EP3328431A1 (enExample) |
| JP (1) | JP2018528175A (enExample) |
| KR (1) | KR20180035859A (enExample) |
| CN (1) | CN108025077A (enExample) |
| AR (1) | AR105533A1 (enExample) |
| AU (1) | AU2016298761A1 (enExample) |
| BR (1) | BR112018001615A2 (enExample) |
| CA (1) | CA2994103A1 (enExample) |
| GB (1) | GB201513441D0 (enExample) |
| IL (1) | IL256995A (enExample) |
| MA (1) | MA42521A (enExample) |
| MX (1) | MX2018001318A (enExample) |
| SG (1) | SG10201913254RA (enExample) |
| TW (1) | TW201713340A (enExample) |
| WO (1) | WO2017017452A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10231248A (ja) * | 1997-02-19 | 1998-09-02 | T T S Gijutsu Kenkyusho:Kk | ジヒドロエトルフィン含有経皮吸収型製剤 |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| CL2004000927A1 (es) * | 2003-04-30 | 2005-01-28 | Purdue Pharma Lp | Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal. |
| TWI541246B (zh) * | 2008-12-08 | 2016-07-11 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
-
2015
- 2015-07-30 GB GBGB1513441.4A patent/GB201513441D0/en not_active Ceased
-
2016
- 2016-07-28 MA MA042521A patent/MA42521A/fr unknown
- 2016-07-28 EP EP16747572.2A patent/EP3328431A1/en not_active Withdrawn
- 2016-07-28 JP JP2018504666A patent/JP2018528175A/ja active Pending
- 2016-07-28 CA CA2994103A patent/CA2994103A1/en not_active Abandoned
- 2016-07-28 AU AU2016298761A patent/AU2016298761A1/en not_active Abandoned
- 2016-07-28 SG SG10201913254RA patent/SG10201913254RA/en unknown
- 2016-07-28 WO PCT/GB2016/052307 patent/WO2017017452A1/en not_active Ceased
- 2016-07-28 BR BR112018001615A patent/BR112018001615A2/pt not_active IP Right Cessation
- 2016-07-28 MX MX2018001318A patent/MX2018001318A/es unknown
- 2016-07-28 US US15/748,548 patent/US20180221299A1/en not_active Abandoned
- 2016-07-28 KR KR1020187005833A patent/KR20180035859A/ko not_active Withdrawn
- 2016-07-28 CN CN201680054263.8A patent/CN108025077A/zh active Pending
- 2016-07-29 AR ARP160102318A patent/AR105533A1/es unknown
- 2016-07-29 TW TW105124084A patent/TW201713340A/zh unknown
-
2018
- 2018-01-18 IL IL256995A patent/IL256995A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3328431A1 (en) | 2018-06-06 |
| CN108025077A (zh) | 2018-05-11 |
| US20180221299A1 (en) | 2018-08-09 |
| AR105533A1 (es) | 2017-10-11 |
| BR112018001615A2 (pt) | 2018-09-18 |
| SG10201913254RA (en) | 2020-03-30 |
| MA42521A (fr) | 2018-06-06 |
| GB201513441D0 (en) | 2015-09-16 |
| KR20180035859A (ko) | 2018-04-06 |
| JP2018528175A (ja) | 2018-09-27 |
| WO2017017452A1 (en) | 2017-02-02 |
| IL256995A (en) | 2018-03-29 |
| AU2016298761A1 (en) | 2018-02-15 |
| CA2994103A1 (en) | 2017-02-02 |
| TW201713340A (zh) | 2017-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500352A1 (en) | Therapeutic uses of empagliflozin | |
| HK1258570A1 (zh) | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| SG10201811454WA (en) | Materials and methods for controlling infections | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| MX2020013740A (es) | Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular. | |
| PH12017501509B1 (en) | Tesofensine, beta blocker combination formulation | |
| EP4137147A3 (en) | Uses of abaloparatide in reducing fracture risk | |
| EP3176163A4 (en) | Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| WO2014152754A3 (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens | |
| SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| WO2017035176A8 (en) | Method of preventing or treating obesity with an emc10 inhibitor | |
| PH12016502322B1 (en) | Compounds and methods for preventing or treating malaria | |
| HK1257171A1 (zh) | 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法 | |
| HK1221166A1 (zh) | 炎症性病症的治疗 | |
| UA117243C2 (uk) | Застосування ландіололу гідрохлориду у тривалому лікуванні тахіаритмії | |
| IL257072A (en) | Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines | |
| MY182591A (en) | Compositions for use in treating eye disorders using dipyridamole | |
| PH12015502037A1 (en) | Activating adiponectin by casein hydrolysate | |
| WO2014026013A3 (en) | Methods for maintaining or improving health, well-being and/or a physiological function in a subject | |
| IN2014DN09240A (enExample) | ||
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| MX2018001318A (es) | Sistema de administracion transdermica. |